ABSTRACT
Bisphosphonates such as zoledronic acid are an important part of adjuvant therapy to reduce the risk of recurrence in early-stage breast cancer. Uveitis remains one of the lesser-known side effects of zoledronic acid; prompt recognition is essential to ensure patients receive appropriate and timely care to help prevent permanent vision loss. We report a case of anterior uveitis in a postmenopausal woman who presented with visual symptoms after receiving the first dose of zoledronic acid. This case report serves to educate and increase awareness of the risk of uveitis in patients who are given zoledronic acid. This is the first and only reported case of zoledronic acid when used in the adjuvant setting for the treatment of breast cancer.
Subject(s)
Bone Density Conservation Agents , Breast Neoplasms , Uveitis , Female , Humans , Zoledronic Acid/adverse effects , Breast Neoplasms/drug therapy , Breast Neoplasms/complications , Bone Density Conservation Agents/adverse effects , Imidazoles/adverse effects , Diphosphonates/adverse effects , Uveitis/chemically induced , Uveitis/complications , Uveitis/drug therapy , Adjuvants, Immunologic , Chemotherapy, Adjuvant/adverse effectsABSTRACT
The use of telemedicine in healthcare settings has continued to increase over the last few years. This has led to new communication-based concerns in palliative care settings. To date, there are no specific guidelines on telemedicine etiqettes relating to conducting online family meetings. This case report discusses some etiquette-failures in a telemedicine family meeting, and offers suggestions to improve communication etiqettes or 'webside manners' in these settings.
